Home Featured Page 256

Featured

Latest

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Red Light Holland Increases Points of Sale for iMicrodose Packs in...

Silo Wellness Announces Five New Psychedelic Wellness Retreats in Jamaica

Beckley Psytech partners with Fluence to create psychedelic therapy training programme

18-MC Has Unique Brain Functions and Mechanisms

Lobe Sciences Appoints Benjamin Kelmendi, MD from Yale University to Scientific...

Nova Mentis Organizes Autism Data Bank in North America

PT240 – Ralph Blumenthal – Alien Abductions and The Believer

Tryp Therapeutics Reports on Key Milestones for 2021

Silo Wellness Appoints Phytomedicine Business Leader as Board Member

PharmaTher Announces Submission of IND Application with the FDA for Phase...

1...255256257...295 Page 256 of 295

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Red Light Holland Increases Points of Sale for iMicrodose Packs in...

Silo Wellness Announces Five New Psychedelic Wellness Retreats in Jamaica

Beckley Psytech partners with Fluence to create psychedelic therapy training programme

18-MC Has Unique Brain Functions and Mechanisms

Lobe Sciences Appoints Benjamin Kelmendi, MD from Yale University to Scientific...

Nova Mentis Organizes Autism Data Bank in North America

PT240 – Ralph Blumenthal – Alien Abductions and The Believer

Tryp Therapeutics Reports on Key Milestones for 2021

Silo Wellness Appoints Phytomedicine Business Leader as Board Member

PharmaTher Announces Submission of IND Application with the FDA for Phase...

EDITOR PICKS

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY